Neurona Therapeutics Advances Rezanecel Toward Phase 3 After 97% Median Seizure Reduction in Long-Term Epilepsy Data 2 weeks ago AnaIn Clinical TrialsTop Stories
GSK Bets $10.6 Billion on Lung Cancer as Nuvalent Acquisition Reshapes Oncology Pipeline 2 weeks ago AnaIn DealsFunding RoundsPartnershipsTop Stories
Australia Approves Amtagvi as First T Cell Immunotherapy for Advanced Melanoma, Targeting the World’s Highest-Burden Population 2 weeks ago AnaIn Biopharma HighlightsBreaking NewsClinical TrialsTop Stories
FDA Clears First PROTAC Therapy in Oncology: Vepdegestrant Approved for ESR1-Mutated Advanced Breast Cancer 2 weeks ago AnaIn Clinical TrialsResearch Updates
NewLimit Raises $435 Million Series C to Advance Epigenetic Reprogramming Platform Targeting Age-Related Disease 3 weeks ago AnaIn Clinical TrialsDealsInvestmentsPartnerships
FDA Grants Dual Approval to Trastuzumab Deruxtecan in Early-Stage HER2-Positive Breast Cancer, Extending ADC Dominance 3 weeks ago AnaIn Breaking NewsClinical TrialsTop Stories
Shionogi’s Ensitrelvir Becomes First Oral Antiviral Approved for Post-Exposure COVID-19 Prevention 3 weeks ago AnaIn Clinical TrialsPharma Industry UpdatesResearch Updates
Tortugas Neuroscience Launches with $106 Million to Advance Four Clinical-Stage CNS Programs Licensed from Eisai and Hansoh 3 weeks ago AnaIn DealsFunding RoundsResearch UpdatesTop Stories
BioMarin Reports Positive Phase 3 Data for VOXZOGO in Hypochondroplasia 3 weeks ago AnaIn Biopharma HighlightsBreaking NewsClinical TrialsTop Stories
FDA Approves VEPPANU (Vepdegestrant), First Oral PROTAC Therapy for ESR1-Mutated Breast Cancer 3 weeks ago AnaIn Biopharma HighlightsBreaking NewsResearch Updates
Alzheimer’s Drug Pipeline Reaches Record Scale in 2026 With 192 Active Trials 3 weeks ago AnaIn Breaking NewsResearch UpdatesTop Stories
Biotech M&A Reaches $106 Billion in 2026 as Pharma Giants Race to Fill Pipelines 3 weeks ago AnaIn Breaking NewsBreakthroughsTop StoriesVenture Capital
Early Alzheimer’s Egg-Shell Protein Therapy Shows Promise in Small Human Study 10 months ago AnaIn Clinical TrialsStartups
Ultragenyx Gene Therapy Rejected by FDA Even as Takeda Scores Big in Narcolepsy Trial 12 months ago AnaIn Clinical TrialsFDA Approvals
FDA Rejects UltraGeneX’s Gene Therapy Application, Pivotal Phase III Reads Out for Takeda Narcolepsy Drug 12 months ago AnaIn Breaking NewsFDA Approvals
